Bismuth
MarketsReal EstateStartupsPlatformFoundersOpportunities
Sign inCreate account
Startup · Coming Soon
Illustrative sample — not a live offering

MedCore Diagnostics

AI diagnostic imaging platform for radiology workflows with hospital LOIs and FDA milestone exposure.

Read MemoReview data room
Bismuth Score74/100
Minimum$1,000
TargetVenture upside
Horizon6-10 years
RiskHigh
Raise$5M Pre-Series A
Investment File
Illustrative sample — not a live offering

MedCore Diagnostics underwriting file

74/100 · High risk · Coming Soon

Startup sample file is shown as a preview sample. Current Bismuth score places it as a watchlist candidate; requires tight sizing and explicit downside controls.

Bismuth organizes sponsor profile, asset plan, capital economics, diligence status, and access assumptions into one research file. This page demonstrates the format and is not an offer to invest.

Sample review read74/100 · High risk · Coming Soon

Startup sample file is shown as a preview sample. Current Bismuth score places it as a watchlist candidate; requires tight sizing and explicit downside controls.

Next diligence checkpointHospital Demand

LOIs received; signed commercial contracts still pending.

Sample access terms$1,000 minimum · 0% illustrative interest

Illustrative only: $5M Pre-Series A sample raise size with venture upside over a 6-10 years horizon.

File Status74/100
Report typeStartup sample memo
Review dateMay 2026
Diligence status0/4 reviewed
Update cycleRegulatory milestone updates plus pilot KPI refresh
01

Builder / Sponsor

Sponsor
MedCore Diagnostics

AI-health startup developing radiology workflow software

Base
Boston, MA

Primary operating market for this opportunity.

Track record
Clinical founding team with hospital pilot access and radiology workflow experience.

Relevant delivery and exit history tracked by Bismuth.

02

Asset / Product Scope

Program
AI diagnostic imaging workflow platform

MedCore is a regulated workflow asset, not a generic AI tool. Investment merit depends on clinical evidence, FDA pathway execution, hospital integration friction, and conversion of LOIs into contracted deployments.

Asset 01
Imaging triage model

Included in the current underwriting scope.

Asset 02
Radiologist workflow UI

Included in the current underwriting scope.

Asset 03
Hospital integration layer

Included in the current underwriting scope.

Asset 04
Validation and audit reports

Included in the current underwriting scope.

03

Economics

Model
Clinical SaaS with usage-linked pricing

The revenue model is enterprise clinical SaaS with usage-linked upside. Committee risk remains regulatory timing, validation strength, procurement cycle length, and reimbursement clarity.

Driver 01
Hospital SaaS contracts

Tracked as a core source of value creation.

Driver 02
Per-study usage fees

Tracked as a core source of value creation.

Driver 03
Enterprise deployment

Tracked as a core source of value creation.

Driver 04
Workflow analytics modules

Tracked as a core source of value creation.

04

Capital Economics

Raise
$5M

Round size currently targeted before FDA milestone.

Hospital LOIs
3

Signed letters of intent from hospital networks.

Projected Burn
$220K

Estimated monthly operating burn after hiring plan.

Runway
22 mo

Expected cash runway after close.

Investment Committee Memo

Investment rationale

74/100 · High risk · Coming Soon

Startup sample file is shown as a preview sample. Current Bismuth score places it as a watchlist candidate; requires tight sizing and explicit downside controls.

The opportunity has meaningful upside if clinical validation and regulatory clearance progress, but Bismuth requires deeper diligence on accuracy, workflow integration, reimbursement, and sales cycle durability.

✓FDA pathway
✓Radiology workflow
✓Hospital LOIs
✓Boston AI-health cluster
Sample File0% modeled interest
SponsorMedCore Diagnostics
LocationBoston · Pre-Series A
ReviewMay 2026
Key Metrics
Raise$5M

Current round target.

Hospital LOIs3

Signed letters of intent.

FDAQ3 2026

Regulatory milestone under review.

StagePilot

Current commercial stage.

Risk Review
HighRegulatory delay
MediumClinical validation
WatchHospital sales cycles
WatchReimbursement uncertainty
Financial Snapshot
Raise$5M

Round size currently targeted before FDA milestone.

Hospital LOIs3

Signed letters of intent from hospital networks.

Projected Burn$220K

Estimated monthly operating burn after hiring plan.

Runway22 mo

Expected cash runway after close.

StagePilot

Current stage of commercialization.

FDA MilestoneQ3 2026

Next regulatory checkpoint in management plan.

Use of Funds
Regulatory32%

Clinical validation, labeling, and regulatory counsel.

R&D34%

Model training, MLOps, integrations, and security.

Pilots21%

Hospital pilots, implementation support, and clinical success.

Runway Reserve13%

Operating reserve through FDA milestone.

Market / News Signals

What changed around this opportunity

Area, sector, and diligence signals that Bismuth tracks before any real review. These sample cards demonstrate the format used for source-aware refresh and research workflows.

Digital Health MonitorMay 2026

Radiology capacity pressure supports clinical AI workflow demand

Radiology workflow pressure continues to support AI triage adoption, especially where staffing gaps create measurable operational pain.

Positive
Regulatory DeskMay 2026

Regulatory pathway controls the investment timeline

The next re-rating event is clinical validation and FDA pathway clarity, not commercial storytelling.

Watch
Live article feed

Connecting article feed...

Team / Operators
DE
Dr. Ethan MilesCo-founder & CMO

Radiologist founder responsible for clinical validation and hospital relationships.

SK
Sarah KimCo-founder & CTO

ML engineer leading model training, data pipeline, and product architecture.

NC
Northstar Clinical AdvisorsAdvisor Group

Former hospital IT executive advising integration and procurement.

Bismuth Diligence
Hospital Demand

LOIs received; signed commercial contracts still pending.

Reviewing
Regulatory Pathway

FDA pathway has been mapped but not completed.

Pending
Clinical Evidence

Clinical validation package is under medical advisor review.

Reviewing
Security Review

Cybersecurity and HIPAA controls require final audit.

Pending
Timeline

Investment process

CurrentClinical package review

Q2 2026

NextFDA milestone

Q3 2026

NextPilot expansion

Q4 2026

Bismuth

Premium AI investment intelligence across markets, real estate, startups, private opportunities and portfolio decisions.

Research onlyPrimary sourcesNo money held
PlatformAI platformMarketsStocks desk
Asset RoomsReal estateStartupsOpportunitiesFounders
AccessCreate accountSign inYour portfolioOpportunity accessRisk disclosures
CompanyAbout BismuthPrivacy policyTerms of serviceContact
What Bismuth is

Bismuth Industries is a research and analysis tool. It is not a broker-dealer, not a registered investment adviser, and not regulated as either. It holds no client money, custodies no assets, places no orders and executes no trades. The order ticket in the stocks desk records simulated positions in your own browser and reaches no market. To buy or sell anything, you use a licensed broker.

© 2026 Bismuth Industries. All rights reserved.

Not investment advice and not an offer to sell securities. AI-generated commentary can be incomplete or wrong and is labelled where it appears. All investments involve risk, including possible loss of principal.